Skip to content

Feasibility, acceptability and evaluation of meditation to augment yoga practice among persons diagnosed with schizophrenia.

Triptish Bhatia, Nupur Kumari, Ashok Yadav, Ram Pratap Beniwal, Gyandeepak Shah, Wood Joel, Jacquelynn R Jones, Satish Iyenger, Vishwajit L Nimgaonkar, Smita N Deshpande

Acta Neuropsychiatrica May 19, 2022 DOI: 10.1017/neu.2022.14 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Single-blind randomised controlled trial Randomized Peer reviewed
Sample size 145
Population Medicated, clinically stable outpatients diagnosed with schizophrenia
Intervention yoga training
Duration 3-week intervention with assessments at 3 weeks and 3 months post-randomisation
Topics Meditation
Keywords Humans Yoga Feasibility studies Single-blind method Schizophrenia Quality of life Cognition Randomised controlled trial
Key findings The meditation-and-yoga program was feasible and acceptable, with no group differences in compliance, discontinuation, or side effects. Clinical changes were in the desired direction and effect sizes were larger in the meditation-and-yoga group than treatment as usual at both three weeks and three months, though all effect sizes were small to medium. The authors conclude it shows modest benefits and warrants larger, longer studies.

Abstract

Objective: To design a meditation protocol and test its feasibility, acceptability and efficacy in conjunction with yoga training (YT) for persons with schizophrenia (SZ).

Methods: The meditation protocol consisted of Anapana (observing normal respiration) and Yoga Nidra (supine, restful awareness). In a single-blind randomised controlled trial, medicated and clinically stable outpatients diagnosed with SZ were randomised to receive treatment as usual (TAU), TAU augmented with YT or TAU augmented with meditation and yoga training (MYT) for 3 weeks (N = 145). Acceptability, clinical, social and cognitive functions were assessed after 3-week and 3-month post-randomisation using within-group and between-group analyses with repeated measures multivariate tests.

Results: No group-wise differences in compliance, study discontinuation, major/serious side effects or adverse events were noted. For six assessed clinical variables, the direction of changes were in the desired direction and the effect sizes were greater in the MYT group compared with the TAU group at both time points. Changes in social function variables were greater at 3 months than at 3 weeks. Nominally significant improvement in individual cognitive domains were noted in all groups at both time points. All effect sizes were in the small to medium range.

Conclusion: MYT is feasible and acceptable and shows modest benefits for persons with SZ. MYT can also improve quality of life and clinical symptoms. Larger studies of longer duration are warranted.

Comparable studies

Other randomized controlled trials on meditation, most cited first.

Study Year Design Participants
Alterations in Brain and Immune Function Produced by Mindfulness Meditation Healthy employees in a work environment 2003 Randomized controlled trial n = 41
Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. Recovered recurrently depressed patients 2000 Randomized controlled trial n = 145
Open hearts build lives: Positive emotions, induced through loving-kindness meditation, build consequential personal resources. Working adults 2008 Randomized controlled trial n = 139
Short-term meditation training improves attention and self-regulation Undergraduate Chinese students 2007 Randomized controlled trial n = 40
Mindfulness-Based Cognitive Therapy for Depression: Replication and Exploration of Differential Relapse Prevention Effects. Recovered recurrently depressed patients 2004 Randomized controlled trial n = 73

Citations in the library

Explore topics